Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization

Launched by FIRST AFFILIATED HOSPITAL OF CHENGDU MEDICAL COLLEGE · Jan 19, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how certain substances in the blood, called catecholamines, change during a specific treatment for high blood pressure caused by conditions like primary aldosteronism. The treatment being studied is called selective adrenal artery embolization (SAAE), which is a procedure that aims to reduce blood pressure by targeting the adrenal glands. The researchers want to understand how this procedure affects blood pressure and catecholamine levels in patients with resistant hypertension, which means their high blood pressure doesn't respond well to regular treatments.

To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of primary aldosteronism. They should have high blood pressure that's been present for over six months and must have undergone certain tests, like blood sampling and imaging of the adrenal glands. Participants will be involved in monitoring their blood pressure and blood samples before and after the SAAE procedure. This study is actively recruiting and welcomes individuals of all genders who meet the eligibility criteria. If you're considering joining, you will need to provide informed consent and discuss any potential risks with the research team.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years with no gender restrictions.
• • 2. Adherence to the "Primary Aldosteronism" Diagnosis and Treatment Guidelines, confirmed diagnosis of primary aldosteronism following rigorous drug washout, and identification as either aldosteronoma or idiopathic aldosteronism via adrenal vein blood sampling.
• • 3. Blood pressure metrics that satisfy any of the subsequent conditions: a) Clinic-recorded blood pressure ≥140/90mmHg; b) 24-hour ambulatory blood pressure monitoring results displaying average blood pressure \>130/80 mmHg or daytime readings \>135/85 mmHg.
• • 4. Adrenal CT scan revealing adrenal hyperplasia, nodular formations, or no significant morphological deviations.
• • 5. Hypertension history surpassing a duration of 6 months.
• • 6. Prior to screening, patients or their lawful guardians must provide a signed informed consent, sanctioned by the ethics committee.
• Exclusion Criteria:
• • 1. Patients diagnosed with primary hypertension or secondary hypertension attributed to other etiologies.
• • 2. Female participants who are presently pregnant, lactating, or with intentions to conceive within the forthcoming year.
• • 3. Presence of significant systemic diseases, with particular attention to hepatic and renal dysfunction.
• • 4. Pronounced allergic reaction to contrast agents.
• • 5. Any other serious systemic diseases with a life expectancy of less than 12 months.
• • 6. Participants concurrently enrolled or expressing interest to participate in other clinical trials, the outcomes of which could potentially influence the results of the current study.
• • 7. The researcher's discretion deems the subject inappropriate for inclusion in the study for any given reason.